仟源医药(300254) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥181,736,278.48, a decrease of 4.09% compared to ¥189,493,463.31 in the same period last year[5] - Net profit attributable to shareholders was ¥10,390,380.78, down 43.17% from ¥18,284,352.36 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥2,790,407.80, a decline of 82.48% compared to ¥15,923,806.26 in the previous year[5] - Basic earnings per share decreased to ¥0.0430, down 43.20% from ¥0.0757 year-on-year[5] - Total operating revenue for the current period is ¥181,736,278.48, a decrease of 4.0% from ¥189,493,463.31 in the previous period[22] - Net profit for the current period is ¥19,195,755.49, a decline of 23.2% compared to ¥24,945,683.88 in the previous period[23] - Earnings per share (basic) decreased to ¥0.0430 from ¥0.0757, reflecting a 43.0% drop[24] Cash Flow - The net cash flow from operating activities was ¥5,157,545.01, representing an 85.47% decrease from ¥35,485,717.14 in the same period last year[5] - Cash flow from operating activities generated ¥5,157,545.01, significantly lower than ¥35,485,717.14 in the previous period[25] - The net cash flow from investing activities was -¥69,573,300, a decrease of 49.21% compared to the previous year[11] - The net cash flow from financing activities was $1,917,133.53, a decrease from $11,056,333.01, suggesting reduced net financing activity[26] - The net cash increase for the period was -$62,498,612.22, contrasting with a minor decrease of -$85,493.74 in the previous period, highlighting cash flow challenges[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,483,632,025.33, a decrease of 4.14% from ¥1,547,725,078.17 at the end of the previous year[5] - Total current assets decreased from CNY 500,868,333.78 to CNY 447,370,510.46, a reduction of approximately 10.65%[19] - Total liabilities decreased from CNY 570,805,532.18 to CNY 466,210,002.45, a reduction of approximately 18.31%[20] - Total liabilities increased to ¥959,415,309.48 from ¥949,545,094.09, indicating a slight rise of 0.9%[21] - Total equity decreased to ¥524,216,715.85 from ¥598,179,984.08, a decline of 12.4%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 21,388[13] - The largest shareholder, Weng Zhangguo, holds 6.35% of shares, totaling 15,772,409 shares[13] - The second largest shareholder, Zhao Qun, holds 5.52% of shares, totaling 13,701,892 shares[13] - The third largest shareholder, Huang Lequn, holds 2.20% of shares, totaling 5,465,060 shares[13] - The top 10 shareholders collectively hold significant stakes, with the largest being 6.35%[13] - The report indicates no changes in the top 10 shareholders due to securities lending or borrowing[14] - There are no preferred shareholders or changes in restricted shares reported[14] Expenses - Total operating costs decreased to ¥173,536,336.36, down 1.4% from ¥176,063,821.72[22] - The company reported a decrease in sales expenses to ¥69,071,111.47 from ¥66,773,310.16, an increase of 3.9%[22] - Research and development expenses rose to ¥12,891,525.28, up from ¥12,048,160.13, reflecting a growth of 7.0%[22] Future Plans and Changes - The company plans to revise its articles of association and waive the preemptive rights for a new shareholder[17] - The company will publish further announcements regarding these matters on the designated information disclosure website[17] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[28] Audit and Reliability - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[27]